Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (NCT02811861)
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).
Who can join: Review the eligibility criteria below.
Location: Stanford School of Medicine — Stanford, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (183 Sites)
Showing the first 25 of 183 sites.
- Stanford School of Medicine — Stanford, California
- Boca Raton Community Hospital — Boca Raton, Florida
- Florida Cancer Specialists — Fort Myers, Florida
- University of Miami — Miami, Florida
- Mount Sinai Medical Center — Miami Beach, Florida
- Florida Hospital Cancer Institute — Orlando, Florida
- Florida Cancer Specialists ( North Region) — St. Petersburg, Florida
- Florida Cancer Specialists — West Palm Beach, Florida
- Joliet Oncology - Hematology Associates — Joliet, Illinois
- Healthcare Research Network III, LLC — Tinley Park, Illinois
- Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC — Overland Park, Kansas
- Cotton-Oneil Clinical Research Center — Topeka, Kansas
- Ochsner Clinic Foundation — New Orleans, Louisiana
- Associates in Oncology & Hematology, PC — Bethesda, Maryland
- Massachusetts General Hospital- MGH — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Karmanos Cancer Center — Detroit, Michigan
- GU Research Network — Omaha, Nebraska
- Nebraska Cancer Specialists — Omaha, Nebraska
- Hackensack Medical Center — Hackensack, New Jersey
- Rosewell Park Cancer Institute — Buffalo, New York
- Broome Oncology — Johnson City, New York
- Weill Cornell Medical College New York Presbyterian Hospital — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center — The Bronx, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
- 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma — Dallas, Texas
- Follow-up After Metastasectomy in Patients With Kidney Cancer — Houston, Texas
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — La Jolla, California
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Los Angeles, California
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.